Author Archive: Roy Zwahlen

Roy Zwahlen

Roy is Associate Counsel at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his three kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.

Latest Posts

House Energy and Commerce Committee Vote Marks Another Step Forward on Pathway to Biosimilars

House Energy and Commerce Committee Vote Marks Another Step Forward on Pathway to Biosimilars Strong bipartisan support for inclusion of pathway in health care reform legislation Washington, D.C. (July 31, 2009) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on the approval of an amendment to create a regulatory pathway for biosimilars by the House Energy and Commerce Committee in today’s mark-up of the America’s Affordable Health Choices Act Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags:

Technology Transfer Symposium at BIO Investor Forum

   Technology Transfer Symposium: Promoting Public-Private Collaboration for Innovation Wednesday October 28, 2009 7:30 am – 12 pm PT The Palace Hotel San Francisco, CA The Technology Transfer Symposium, held in conjunction with the BIO Investor Forum, will explore the domestic and international policy challenges for professionals in university, industry, and legal areas regarding the administration of technology transfer.  This groundbreaking meeting will bring together stakeholder groups to discuss the challenges and opportunities of today’s Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,

New Series: Biotechnology Companies at Forefront of Global Health Innovation – Post #1: GlaxoSmithKline & Alnylam Pharmaceuticals

On July 8 2009, GlaxoSmithKline (GSK) and Alnylam Pharmaceuticals, Inc. announced a patent pool to compile intellectual property (IP) to develop treatments for 16 tropical diseases as identified by the FDA including malaria, TB and Chagas, found in 49 Least Developed Countries as defined by the United Nations.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

Webinar: University Startups: Best Practices

Update: The presentation materials are available here: http://bit.ly/IBfmv (thanks to Jack Pincus, via Twitter) The National Council of Entrepreneurial Tech Transfer (NCET2) is hosting a webinar on university spinouts and the MIT entrepreneurial ecosystem: What Are Universities Doing to Create and Fund University Startups: Best Practices The MIT Entrepreneurial Ecosystem Wednesday, July 29, 1:00-2:30pm ET (10:00-11:30am PT) With Edward B. Roberts (David Sarnoff Professor of the Management of Technology MIT Sloan School of Management; Founder/Chair, MIT Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags:

GAO Report on Bayh-Dole: Leverage to Promote Commercialization of Federally-Funded Inventions

The General Accountability Office submitted its report to Congress today on the administration of the regulations found under the Bayh-Dole Act, the foundation of all federally-funded research in the United States and one of the key factors in the creation (and boom) of biotechnology as both a research field and industry in the 1980s. A little background on Bayh-Dole: Technological innovation is widely seen as responsible for much of the economic growth and increased standard Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,